Perspectives on oxaliplatin in the treatment of gastrointestinal cancersGOLDBERG, Richard M.Seminars in oncology. 2003, Vol 30, Num 4, issn 0093-7754, 70 p., SUP15Serial Issue

Oxaliplatin therapy for the treatment of metastatic colorectal cancerGOLDBERG, Richard M.Seminars in oncology. 2002, Vol 29, Num 5, issn 0093-7754, 41 p., SUP15Serial Issue

First-line treatment strategies to improve survival in patients with advanced colorectal cancerGILL, Sharlene; GOLDBERG, Richard M.Drugs (Basel). 2004, Vol 64, Num 1, pp 27-44, issn 0012-6667, 18 p.Article

Pharmacogenomics in colorectal cancerLENZ, Heinz Josef.Seminars in oncology. 2003, Vol 30, Num 4, pp 47-53, issn 0093-7754, 7 p., SUP15Article

Optimal Management of Metastatic Colorectal Cancer: Current StatusMCREE, Autumn J; GOLDBERG, Richard M.Drugs (Basel). 2011, Vol 71, Num 7, pp 869-884, issn 0012-6667, 16 p.Article

Opportunities for newer agents in combination with oxaliplatinHOCHSTER, Howard S.Seminars in oncology. 2003, Vol 30, Num 4, pp 62-67, issn 0093-7754, 6 p., SUP15Article

The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: Prospects and future directionsSCHMOLL, H. J.Seminars in oncology. 2002, Vol 29, Num 5, pp 34-39, issn 0093-7754, SUP15Article

Treatment of Metastatic Colorectal Cancer : COLORECTAL CANCERDAVIES, Janine M; GOLDBERG, Richard M.Seminars in oncology. 2011, Vol 38, Num 4, pp 552-560, issn 0093-7754, 9 p.Article

A flexible design for multiple armed screening trialsSARGENT, Daniel J; GOLDBERG, Richard M.Statistics in medicine. 2001, Vol 20, Num 7, pp 1051-1060, issn 0277-6715Article

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentGROTHEY, Axel; SARGENT, Daniel; GOLDBERG, Richard M et al.Journal of clinical oncology. 2004, Vol 22, Num 7, pp 1209-1214, issn 0732-183X, 6 p.Article

Optimal use of the combination of irinotecan and 5-fluorouracilBENSON, Al B; GOLDBERG, Richard M.Seminars in oncology. 2003, Vol 30, Num 3, pp 68-77, issn 0093-7754, 10 p., SUP6Article

A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumorsMCREE, Autumn J; DAVIES, Janine M; SANOFF, Hanna G et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 1, pp 117-123, issn 0344-5704, 7 p.Article

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)YOON, Harry H; TOUGERON, David; SINICROPE, Frank A et al.Clinical cancer research (Print). 2014, Vol 20, Num 11, pp 3033-3043, issn 1078-0432, 11 p.Article

Body Mass Index at Diagnosis and Survival Among Colon Cancer Patients Enrolled in Clinical Trials of Adjuvant ChemotherapySINICROPE, Frank A; FOSTER, Nathan R; YOTHERS, Greg et al.Cancer. 2013, Vol 119, Num 8, pp 1528-1536, issn 0008-543X, 9 p.Article

Identification of Potential Prognostic Biomarkers in Patients With Untreated, Advanced Pancreatic Cancer From a Phase 3 Trial (Cancer and Leukemia Group B 80303)ROBERTS, Andrew S; CAMPA, Michael J; GOTTLIN, Elizabeth B et al.Cancer. 2012, Vol 118, Num 2, pp 571-578, issn 0008-543X, 8 p.Article

Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841FRANKO, Jan; QIAN SHI; GOLDMAN, Charles D et al.Journal of clinical oncology. 2012, Vol 30, Num 3, pp 263-267, issn 0732-183X, 5 p.Article

Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741NG, Kimmie; SARGENT, Daniel J; GOLDBERG, Richard M et al.Journal of clinical oncology. 2011, Vol 29, Num 12, pp 1599-1606, issn 0732-183X, 8 p.Article

_P27 ^Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803BERTAGNOLLI, Monica M; WARREN, Robert S; GOLDBERG, Richard M et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 2116-2122, issn 1078-0432, 7 p.Article

Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841KIM, George P; SARGENT, Daniel J; PITOT, Henry C et al.Journal of clinical oncology. 2009, Vol 27, Num 17, pp 2848-2854, issn 0732-183X, 7 p.Article

Association of Family History With Cancer Recurrence and Survival Among Patients With Stage III Colon Cancer. CommentaryCHAN, Jennifer A; MEYERHARDT, Jeffrey A; GOLDBERG, Richard M et al.JAMA, the journal of the American Medical Association. 2008, Vol 299, Num 21, issn 0098-7484, 1515-1523, 1564-1565 [11 p.]Article

Survival Following Recurrence in Stage II and III Colon Cancer : Findings From the ACCENT Data SetO'CONNELL, Michael J; CAMPBELL, Megan E; GOLDBERG, Richard M et al.Journal of clinical oncology. 2008, Vol 26, Num 14, pp 2336-2341, issn 0732-183X, 6 p.Article

Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : Intergroup trial n9741 in first-line treatment of metastatic colorectal cancerASHLEY, Amanda C; SARGENT, Daniel J; PITOT, Henry C et al.Cancer. 2007, Vol 110, Num 3, pp 670-677, issn 0008-543X, 8 p.Article

Expression of nuclear factor-kappab family proteins in hepatocellular carcinomasO'NEIL, Bert H; BUZKOVA, Petra; FARRAH, Hillary et al.Oncology. 2007, Vol 72, Num 1-2, pp 97-104, issn 0030-2414, 8 p.Article

Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinomaHILLNER, Bruce E; SCHRAG, Deborah; SARGENT, Daniel J et al.Cancer. 2005, Vol 104, Num 9, pp 1871-1884, issn 0008-543X, 14 p.Article

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?GILL, Sharlene; LOPRINZI, Charles L; LABIANCA, Roberto et al.Journal of clinical oncology. 2004, Vol 22, Num 10, pp 1797-1806, issn 0732-183X, 10 p.Article